Second Agreement with Sinclai

RNS Number : 3147V

Syntopix Group plc

01 November 2010

 



Press Release

01 November 2010

Syntopix Group plc

("Syntopix" or "the Company")

Syntopix signs second agreement with Sinclair Pharma

Syntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, is pleased to announce that it has signed a second agreement with Sinclair Pharma plc (LON:SPH) ("Sinclair"), the international speciality pharmaceutical company. Sinclair will pay Syntopix a development contract fee to further develop combination formulations using Sinclair's delmopinol and some potentially synergistic anti-microbial compounds in to proof of concept development formulations. Upon conclusion of the development programme if any of the resultant formulations for oral health and other medical applications are commercialized, Syntopix will receive royalties.

This builds on an initial agreement between the companies announced in April 2010, to work together on the identification of an antimicrobial compound to synergise and augment the anti-biofilm activity of Sinclair's key ingredient already marketed as Decapinol®.

Dr Stephen Jones, CEO of Syntopix, says: "I am delighted that the collaboration Syntopix and Sinclair embarked on in April has been a success.  We have been working closely with Sinclair and are pleased to be able to progress our agreement to the next stage.  As a leading company developing treatments for diseases/problems of the skin and mouth, Sinclair's expertise is closely aligned with our own and together we are in a strong position to develop unique and effective products."

- Ends -

For further information, please contact:

Syntopix Group plc
Dr Stephen Jones, Chief Executive Officer	[phone]
Tom Bannatyne, Chairman	www.syntopix.com

Zeus Capital Ltd
Alex Clarkson	Tel: [phone]
	www.zeuscapital.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins / Simone Elviss / Claire Dickinson	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

Syntopix

Syntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.

Syntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour. 

The Group has a robust research pipeline, with a growing library of over 2,700 compounds (with established safety profiles) profiled both individually and in combination for their antimicrobial activity. The Group, which currently has 12 granted UK patent applications, raised £2 million in March 2010, to undertake clinical studies with its lead compounds and to further develop the pipeline.

Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group plc), The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited.  Syntopix joined the AIM market of the London Stock Exchange in March 2006. For more information, please visit our website at www.syntopix.com.

Sinclair Pharma Plc www.sinclairpharma.com 

Sinclair Pharma plc is an international, highly commercial, rapid-growth dermatology and oral care company providing and promoting high quality and differentiated products through growing sales and marketing operation that is present in France, Italy, Germany and Spain, and through an extensive marketing partner network across selected developed & emerging markets.

Ends -

 

END

 

 

MSCQKLFLBBFFFBZ